Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Ikena Oncology Inc.
Headquarters: Boston, MA, United States of America
Website: https://ikenaoncology.com/
Year Founded: 2016
Status: Public
Industry Sector: HealthTechnology
CEO: Mark Manfredi, PhD
Number Of Employees: 10
Enterprise Value: $-37,721,698
PE Ratio: -1.31
Exchange/Ticker 1: NASDAQ:IKNA
Exchange/Ticker 2: N/A
Latest Market Cap: $53,946,300
BioCentury | Dec 6, 2024
Management Tracks
Sarah Holland named CBO of CDR-Life
Plus: AcuraStem hires van der Brug as CSO and an update from Atlas
BioCentury | Dec 5, 2024
Finance
Broadening Versant’s obesity portfolio, Antag plots clinical path with €80M
Also in BioCentury’s weekly Venture Report: Formela stepping back from Atlas’ new fund, nine-digit rounds for Nuvig and Maze, and more
BioCentury | Sep 10, 2024
Management Tracks
Vir names Jason O’Byrne CFO
Plus: Maslowski to become CEO of Forge as Miller steps down, and updates from Sofinnova Partners, Abingworth, PATH and more
BioCentury | May 30, 2024
Product Development
Clinical Report: Phase III win for J&J in neuropsychiatry; Biohaven falls on BHV-1300 data
Plus: Insmed gets boost from bronchiectasis readout and updates from HI-Bio, Corcept, Tango and Ikena
BioCentury | Feb 23, 2024
Management Tracks
New chair, management changes at Ocular
Plus: Jason Gammack named CEO of Ansa, and updates from LenioBio, Prothena and Ikena
BioCentury | Feb 15, 2024
Emerging Company Profile
BridGene: a pairwise approach to chemoproteomics for hard targets
The California company’s IMTAC screening platform for hard-to-drug targets has found partners in Takeda and Galapagos
BioCentury | Aug 24, 2023
Finance
Aug. 23 Quick Takes: CVS launches biosimilar subsidiary
Plus: Foundery raising $160M for first fund, Apellis shares bounce back and updates from Cellares, Agenus, Pfizer, Astellas and more
BioCentury | Aug 8, 2023
Deals
Aug. 7 Quick Takes: Eyeing cash, Ikena buys Pionyr
Plus: Astellas’ Zimura approved for geographic atrophy, Bavarian’s chikungunya vaccine heading to regulators and updates from Gracell, IO, Sage, Nektar and DotBio
BioCentury | Dec 20, 2022
Management Tracks
Nolan succeeding Session as CEO of Taysha
Plus: Carmona named CFO at ADC, and updates from NewAmsterdam, CRISPR, Ikena, CN bio and more
BioCentury | May 4, 2022
Management Tracks
Hickey returns to U.S. for new role at Pfizer
Plus Kaundinya named president and CEO at GlycoERA, and updates from Plexium, Alentis, ADCendo, Xcell and more
Items per page:
1 - 10 of 20